Duyuru • Apr 24
Antibe Therapeutics Inc. Announces Board Resignations Antibe Therapeutics Inc. announced that Roderick Flower, Robert Hoffman, Dan Legault, Walt Macnee and Yung Wu have resigned from Antibe’s Board of Directors. Duyuru • Apr 09
Antibe Therapeutics Inc. Announces Board Resignations Antibe Therapeutics Inc. announced that Amal Khouri and Jennifer McNealey have resigned from its Board of Directors effective April 8, 2024. New Risk • Apr 02
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: CA$8.75m (US$6.44m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (24% average weekly change). Revenue is less than US$1m. Market cap is less than US$10m (CA$8.75m market cap, or US$6.44m). Minor Risk Currently unprofitable and not forecast to become profitable over next 3 years (CA$25m net loss in 3 years). Price Target Changed • Mar 07
Price target decreased by 14% to CA$1.50 Down from CA$1.75, the current price target is an average from 4 analysts. New target price is 188% above last closing price of CA$0.52. Stock is up 8.3% over the past year. The company is forecast to post a net loss per share of CA$0.40 next year compared to a net loss per share of CA$0.37 last year. New Risk • Feb 14
New minor risk - Profitability The company is currently unprofitable and not forecast to become profitable over the next 3 years. Trailing 12-month net loss: CA$18m Forecast net loss in 3 years: CA$10m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (CA$10m net loss in 3 years). Market cap is less than US$100m (CA$47.1m market cap, or US$34.7m). Board Change • Dec 02
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. 3 highly experienced directors. Independent Chair of the Board Robert Hoffman was the last director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment. Duyuru • Nov 10
Antibe Therapeutics Inc. Reports PK Results of First Clinical Study of Otenaproxesul’s New Formulation Antibe Therapeutics Inc. announced the PK results of the pharmacokinetic/pharmacodynamic ("PK/PD") study of otenaproxesul's faster-absorbing formulation. The study was designed to confirm the drug's safety and inform the selection of treatment regimens for the upcoming Phase II trial, on track to launch in calendar First Quarter 2024. The PK/PD study involved 36 healthy volunteers, randomized across three treatment arms: a single high dose and two five-day regimens of o tenaproxesul. Subjects remained in-clinic for the duration of their treatment. As previously reported, all subjects completed the study with no clinically significant, drug-related adverse events and no increase in liver enzymes. In line with preclinical data and DILIsym liver safety modeling, the study confirmed the new formulation's linear, dose-proportional PK, with substantially lower doses needed to achieve target plasma levels compared to the original formulation. More rapid elimination was also observed, expanding the drug's safety envelope. These data provide the basis for selecting treatment regimens to achieve the pain relief expectations of patients, doctors and regulators. They also advance Antibe's exploration of potential treatment regimens for chronic pain. New Risk • Nov 10
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Canadian stocks, typically moving 14% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m. Minor Risks Share price has been volatile over the past 3 months (14% average weekly change). Market cap is less than US$100m (CA$62.1m market cap, or US$45.0m). Duyuru • Nov 02
Antibe Completes First Clinical Study of Otenaproxesul’s New Formulation Antibe Therapeutics Inc. announced the completion of the pharmacokinetic/pharmacodynamic (“PK/PD”) study of otenaproxesul’s faster-absorbing formulation for acute pain. The study was designed to confirm the drug’ssafety and inform treatment regimens for the upcoming Phase II trial, on track to launch in calendar First Quarter 2024. The PK/PD study involved 36 healthy volunteers randomized across three treatment arms: a single high dose and two five-day regimens of otenaproxesul. The five-day regimens were chosen to correspond to regimens envisaged for the upcoming Phase II trial. Subjects remained in-clinic for the duration of their treatment. All subjectscompleted the study with no clinically significant, drug-related adverse events and no elevation in liver enzymes during treatment or in post-treatment follow up. Duyuru • Oct 19
Antibe Initiates First Clinical Study of Otenaproxesul’s New Formulation Antibe Therapeutics Inc. announce the initiation of the pharmacokinetic/pharmacodynamic (“PK/PD”) study of otenaproxesul’s faster-absorbing formulation for acute pain. The study is designed to inform the doses and confirm safety in preparation for the Phase II trial, on track to launch in calendar First Quarter 2024. The PK/PD study will involve 36 healthy volunteers randomized across three treatment arms: a single high dose and two five-day regimens of otenaproxesul. Subjects will remain in-clinic for the duration of their treatment. Expected in November, the study data will also advance Antibe’s exploration of potential treatment regimens for chronic pain. Duyuru • Sep 29
Antibe Therapeutics Inc. Receives Approval to Initiate PK/PD Study of Otenaproxesul Antibe Therapeutics Inc. announced Health Canada's approval to initiate the pharmacokinetic/pharmacodynamic study of otenaproxesul's faster-absorbing formulation for acute pain. Set to commence in October, the purpose of the study is to inform the doses for the Phase II trial. New Risk • Aug 17
New minor risk - Profitability The company is currently unprofitable and not forecast to become profitable over the next 3 years. Trailing 12-month net loss: CA$19m Forecast net loss in 3 years: CA$5.6m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (CA$5.6m net loss in 3 years). Market cap is less than US$100m (CA$29.5m market cap, or US$21.8m). Breakeven Date Change • Aug 15
No longer forecast to breakeven The 4 analysts covering Antibe Therapeutics no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of CA$1.12m in 2026. New consensus forecast suggests the company will make a loss of CA$3.09m in 2026. New Risk • Aug 15
New minor risk - Profitability The company is currently unprofitable and not forecast to become profitable over the next 3 years. Trailing 12-month net loss: CA$19m Forecast net loss in 3 years: CA$3.1m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (CA$3.1m net loss in 3 years). Market cap is less than US$100m (CA$30.0m market cap, or US$22.3m). Duyuru • Jul 01
Antibe Therapeutics Inc., Annual General Meeting, Sep 08, 2023 Antibe Therapeutics Inc., Annual General Meeting, Sep 08, 2023. Location: Toronto, ON Toronto Canada Breakeven Date Change • Jun 30
Forecast to breakeven in 2026 The 4 analysts covering Antibe Therapeutics expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of CA$1.12m in 2026. Average annual earnings growth of 66% is required to achieve expected profit on schedule. Price Target Changed • Apr 02
Price target increased by 12% to CA$2.35 Up from CA$2.09, the current price target is an average from 5 analysts. New target price is 292% above last closing price of CA$0.60. Stock is down 23% over the past year. The company posted a net loss per share of CA$0.50 last year. Duyuru • Feb 16
Antibe Therapeutics Inc. Announces Retirement of Dr. John L. Wallace from the Board of Directors Antibe Therapeutics Inc. announced that its founder, Dr. John L. Wallace, has decided to retire from the Board of Directors. Dr. Wallace will remain a corporate Vice Chair, enabling the company to continue to benefit from his wisdom and expertise. Price Target Changed • Jan 04
Price target increased to CA$2.35 Up from CA$2.09, the current price target is an average from 5 analysts. New target price is 370% above last closing price of CA$0.50. Stock is down 25% over the past year. The company is forecast to post a net loss per share of CA$0.49 next year compared to a net loss per share of CA$0.50 last year. Recent Insider Transactions • Dec 21
Founder & Vice Chair recently sold CA$122k worth of stock On the 13th of December, John Wallace sold around 250k shares on-market at roughly CA$0.49 per share. This transaction amounted to 14% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. John has been a net seller over the last 12 months, reducing personal holdings by CA$213k. Price Target Changed • Nov 16
Price target decreased to CA$2.09 Down from CA$2.26, the current price target is an average from 6 analysts. New target price is 323% above last closing price of CA$0.49. Stock is down 42% over the past year. The company is forecast to post a net loss per share of CA$0.48 next year compared to a net loss per share of CA$0.50 last year. Duyuru • Nov 03
HANSAmed Limited completed the acquisition of Citagenix Inc from Antibe Therapeutics Inc. (TSX:ATE) for CAD 6.5 million. HANSAmed Limited entered into an agreement to acquire Citagenix Inc. from Antibe Therapeutics Inc. (TSX:ATE) for CAD 6.5 million on May 2, 2022. The CAD 6.5 million transaction involves a guaranteed CAD 3.5 million, divided into four equal payments over three years, the first of which will be received at closing. The remaining CAD 3 million is subject to Citagenix achieving sales milestones over the three-year period following closing. The transaction will close no later than 180 days following the signing of this binding agreement.
HANSAmed Limited completed the acquisition of Citagenix Inc from Antibe Therapeutics Inc. (TSX:ATE) for CAD 6.5 million on November 2, 2022. Duyuru • Oct 13
Antibe Therapeutics Inc. Provides Development Update for Otenaproxesul Antibe Therapeutics Inc. announced a major advance in otenaproxesul’s formulation that promises to increase its therapeutic benefit and commercial potential. Accordingly, the Company has filed a patent application that strengthens the drug’s IP protection to 2042. The new formulation’s benefits include: (i) rapid dissolution mechanics, accelerating otenaproxesul’s onset of action, a key benchmark for acute pain medications; and (ii) enhanced bioavailability, enabling a significant dose reduction compared to its current formulation. The lower dose provides an additional safety buffer as well as a potential pathway to address chronic pain indications. The new formulation was developed in collaboration with Antibe’s global manufacturing partner; all related IP is owned exclusively by Antibe. Price Target Changed • Aug 19
Price target decreased to CA$2.09 Down from CA$2.26, the current price target is an average from 5 analysts. New target price is 227% above last closing price of CA$0.64. Stock is down 44% over the past year. The company is forecast to post a net loss per share of CA$0.48 next year compared to a net loss per share of CA$0.50 last year. Reported Earnings • Aug 16
First quarter 2023 earnings released: CA$0.11 loss per share (vs CA$0.13 loss in 1Q 2022) First quarter 2023 results: CA$0.11 loss per share (up from CA$0.13 loss in 1Q 2022). Net loss: CA$5.60m (loss narrowed 11% from 1Q 2022). Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has fallen by 44% per year, which means it is significantly lagging earnings. Recent Insider Transactions • Jul 20
Founder & Vice Chair recently sold CA$88k worth of stock On the 12th of July, John Wallace sold around 143k shares on-market at roughly CA$0.62 per share. This was the largest sale by an insider in the last 3 months. John has been a seller over the last 12 months, reducing personal holdings by CA$35k. Price Target Changed • Jul 06
Price target decreased to CA$2.93 Down from CA$3.49, the current price target is an average from 5 analysts. New target price is 372% above last closing price of CA$0.62. Stock is down 84% over the past year. The company is forecast to post a net loss per share of CA$0.48 next year compared to a net loss per share of CA$0.50 last year. Duyuru • Jul 05
Antibe Therapeutics Inc., Annual General Meeting, Sep 09, 2022 Antibe Therapeutics Inc., Annual General Meeting, Sep 09, 2022. Duyuru • May 26
Antibe Therapeutics Appoints New Board Chair and Corporate Vice Chairs Antibe Therapeutics Inc. announced the appointment of Robert E. Hoffman, a Director of Antibe, as the new Chair of its Board of Directors. The Company is also creating two corporate Vice Chair positions to recognize the contributions of Walt Macnee, the outgoing Chair, and Dr. John L. Wallace, Chief Scientific Officer and Director since he founded the Company. As Vice Chairs, they will occupy an esteemed corporate position, providing ongoing counsel to the Company on key business initiatives; Antibe is pleased to note that they will both continue to serve on its Board of Directors. Dr. Wallace is also taking the opportunity to return to his vocation as a research scientist, with a continued focus on enriching the Company’s pipeline. A member of Antibe’s Board since late 2020, Robert E. Hoffman is former CFO of Nasdaq-listed Heron Pharmaceuticals, a commercial stage drug developer with a recently approved acute pain drug. During Mr. Hoffman’s tenure, Heron raised more than $650 million and launched its second commercial therapeutic. His career in the biotech sector began in 1997 at Arena Pharmaceuticals, where he rose to become CFO. While at Arena, he was involved with its IPO and financings raising more than $1.5 billion. For 10 years until 2020, Mr. Hoffman was a member of the Small Business Advisory Committee of the Financial Accounting Standards Board. He is currently President, CEO and Chairman of Kintara Therapeutics and a member of the boards of ASLAN Pharmaceuticals (Nasdaq) and privately held FibroBiologics. Duyuru • May 03
HANSAmed Limited entered into an agreement to acquire Citagenix Inc. from Antibe Therapeutics Inc. (TSX:ATE) for CAD 6.5 million HANSAmed Limited entered into an agreement to acquire Citagenix Inc. from Antibe Therapeutics Inc. (TSX:ATE) for CAD 6.5 million on May 2, 2022. The CAD 6.5 million transaction involves a guaranteed CAD 3.5 million, divided into four equal payments over three years, the first of which will be received at closing. The remaining CAD 3 million is subject to Citagenix achieving sales milestones over the three-year period following closing. The transaction will close no later than 180 days following the signing of this binding agreement. Major Estimate Revision • Feb 22
Consensus revenue estimates increase by 112% The consensus outlook for revenues in 2022 has improved. 2022 revenue forecast increased from CA$1.81m to CA$3.83m. Forecast losses expected to reduce from -CA$0.58 to -CA$0.51 per share. Pharmaceuticals industry in Canada expected to see average net income growth of 40% next year. Consensus price target of CA$2.53 unchanged from last update. Share price rose 7.2% to CA$0.74 over the past week. Price Target Changed • Feb 16
Price target decreased to CA$2.53 Down from CA$2.91, the current price target is an average from 4 analysts. New target price is 251% above last closing price of CA$0.72. Stock is down 90% over the past year. The company is forecast to post a net loss per share of CA$0.51 next year compared to a net loss per share of CA$0.66 last year. Major Estimate Revision • Dec 03
Consensus revenue estimates increase to CA$1.81m The consensus outlook for revenues in 2022 has improved. 2022 revenue forecast increased from CA$1.36m to CA$1.81m. Forecast losses expected to reduce from -CA$0.61 to -CA$0.57 per share. Pharmaceuticals industry in Canada expected to see average net income growth of 42% next year. Consensus price target down from CA$2.91 to CA$2.74. Share price fell 10% to CA$0.70 over the past week. Major Estimate Revision • Dec 02
Consensus forecasts updated The consensus outlook for 2022 has been updated. 2022 losses forecast to reduce from -CA$0.61 per share to -CA$0.55 per share. Revenue forecast reaffirmed at CA$1.36m. Pharmaceuticals industry in Canada expected to see average net income growth of 42% next year. Consensus price target down from CA$2.91 to CA$2.74. Share price fell 14% to CA$0.67 over the past week. Reported Earnings • Nov 18
Second quarter 2022 earnings released: CA$0.16 loss per share (vs CA$0.21 loss in 2Q 2021) Second quarter 2022 results: Net loss: CA$8.37m (loss widened 5.3% from 2Q 2021). Over the last 3 years on average, earnings per share has fallen by 7% per year but the company’s share price has fallen by 32% per year, which means it is performing significantly worse than earnings. Recent Insider Transactions • Nov 03
President recently bought CA$100k worth of stock On the 1st of November, Daniel Legault bought around 105k shares on-market at roughly CA$0.95 per share. This was the largest purchase by an insider in the last 3 months. Despite this recent buy, Daniel has been a net seller over the last 12 months, reducing personal holdings by CA$159k. Reported Earnings • Aug 18
First quarter 2022 earnings released: CA$0.13 loss per share (vs CA$0.16 loss in 1Q 2021) The company reported a solid first quarter result with improved revenues and control over costs, although losses increased. First quarter 2022 results: Revenue: CA$2.73m (up 122% from 1Q 2021). Net loss: CA$6.30m (loss widened 28% from 1Q 2021). Over the last 3 years on average, earnings per share has fallen by 12% per year but the company’s share price has fallen by 26% per year, which means it is performing significantly worse than earnings. Major Estimate Revision • Aug 05
Consensus forecasts updated The consensus outlook for 2022 has been updated. 2022 losses forecast to reduce from -CA$0.62 to -CA$0.53 per share. Revenue forecast steady at CA$9.84m. Pharmaceuticals industry in Canada expected to see average net income growth of 120% next year. Consensus price target down from CA$14.53 to CA$7.96. Share price fell 66% to CA$1.16 over the past week. Price Target Changed • Aug 04
Price target decreased to CA$10.20 Down from CA$14.53, the current price target is an average from 7 analysts. New target price is 890% above last closing price of CA$1.03. Stock is down 77% over the past year. Breakeven Date Change • Jul 02
No longer forecast to breakeven The 7 analysts covering Antibe Therapeutics no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of CA$4.96m in 2024. New consensus forecast suggests the company will make a loss of CA$23.0m in 2024. Breakeven Date Change • Jun 30
No longer forecast to breakeven The 5 analysts covering Antibe Therapeutics no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of CA$4.96m in 2024. New consensus forecast suggests the company will make a loss of CA$23.0m in 2024. Reported Earnings • Jun 30
Full year 2021 earnings released: CA$0.66 loss per share (vs CA$0.71 loss in FY 2020) The company reported a poor full year result with increased losses, weaker revenues and weaker control over costs. Full year 2021 results: Revenue: CA$9.71m (down 2.7% from FY 2020). Net loss: CA$24.7m (loss widened 28% from FY 2020). Over the last 3 years on average, earnings per share has fallen by 15% per year but the company’s share price has only fallen by 1% per year, which means it has not declined as severely as earnings. Price Target Changed • Jun 19
Price target decreased to CA$15.09 Down from CA$16.96, the current price target is an average from 6 analysts. New target price is 297% above last closing price of CA$3.80. Stock is down 16% over the past year. Recent Insider Transactions • Jun 08
Independent Chair of the Board recently sold CA$400k worth of stock On the 3rd of June, Walter MacNee sold around 100k shares on-market at roughly CA$4.00 per share. This was the largest sale by an insider in the last 3 months. This was Walter's only on-market trade for the last 12 months. Duyuru • Feb 25
Antibe Therapeutics Inc. has completed a Composite Units Offering in the amount of CAD 35.1 million. Antibe Therapeutics Inc. has completed a Composite Units Offering in the amount of CAD 35.1 million.
Security Name: Units
Security Type: Equity/Derivative Unit
Securities Offered: 5,850,000
Price\Range: CAD 6
Discount Per Security: CAD 0.36 Price Target Changed • Feb 24
Price target raised to CA$16.96 Up from CA$15.75, the current price target is an average from 5 analysts. The new target price is 209% above the current share price of CA$5.48. As of last close, the stock is down 13% over the past year. Reported Earnings • Feb 13
Third quarter 2021 earnings released: CA$0.15 loss per share (vs CA$0.15 loss in 3Q 2020) The company reported a soft third quarter result with increased losses and weaker control over costs, although revenues improved. Third quarter 2021 results: Revenue: CA$2.79m (up 7.0% from 3Q 2020). Net loss: CA$5.93m (loss widened 41% from 3Q 2020). Over the last 3 years on average, earnings per share has fallen by 17% per year but the company’s share price has increased by 27% per year, which means it is well ahead of earnings. Analyst Estimate Surprise Post Earnings • Feb 13
Revenue and earnings beat expectations Revenue exceeded analyst estimates by 1.8%. Earnings per share (EPS) also surpassed analyst estimates by 16%. Over the next year, revenue is forecast to grow 37%, compared to a 261% growth forecast for the Pharmaceuticals industry in Canada. Major Estimate Revision • Feb 12
Analysts update estimates The company's losses in 2021 are expected to improve with analysts raising their consensus EPS forecasts from -CA$0.53 to -CA$0.44. No change was made to the revenue estimate which at the last update was CA$9.46m. The Pharmaceuticals industry in Canada is expected to see a 55% decline in net income next year. The consensus price target increased from CA$15.75 to CA$16.63. Share price is up 36% to CA$5.48 over the past week. Duyuru • Feb 10
Nuance Pharma Announces Strategic Licensing Deal with Antibe Therapeutics in China Antibe Therapeutics Inc. announced that it has licensed otenaproxesul to Nuance Pharma for commercialization in the Greater China region. Nuance is a biopharmaceutical company focused on licensing, developing and commercializing globally innovative therapies to address critical unmet medical needs in China and other Asia Pacific markets. Founded by Mark Lotter who built the AstraZeneca commercial franchise in China, and led by executives with extensive multinational pharma experience, Nuance focuses on identifying and in-licensing therapies that have achieved best-in-class, human proof-of-concept status. The license provides Nuance with exclusive rights to commercialize the otenaproxesul in mainland China, Hong Kong, Macau, and Taiwan, representing approximately 10% of the worldwide pharma market. Under the terms of the agreement, Antibe is entitled to USD 100 million in milestone payments, including USD 20 million upfront and USD 80 million in development and sales milestones, in addition to a double-digit royalty on sales. Clinical development and regulatory costs for the region will be borne by Nuance. Antibe and Nuance have established a structure for collaborating on otenaproxesul's clinical development in the region, ensuring a fit with Antibe's global regulatory strategy. Is New 90 Day High Low • Feb 10
New 90-day high: CA$5.76 The company is up 42% from its price of CA$4.05 on 11 November 2020. The Canadian market is up 11% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Pharmaceuticals industry, which is up 92% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CA$59.39 per share. Duyuru • Jan 09
Antibe Therapeutics Inc. Appoints Don Haut to Its Partnering Advisory Team Antibe Therapeutics Inc. announced the appointment of Dr. Don Haut to its Partnering Advisory Team. Most recently, Dr. Haut was Chief Business Officer of AskBio. He led the firm’s business development activities, completing four transactions in 2020 before taking a leading role in AskBio’s $4 billion acquisition by Bayer AG. In a career spanning academic science, consulting, sales management, and business development, he has completed transactions exceeding $8 billion and been instrumental in multiple product launches. He has also served on the boards of several healthcare companies, including firms involved in joint replacement and repair. Originally trained as a molecular biologist before joining McKinsey, Dr. Haut has since held senior business roles at 3M Company, Smith & Nephew, and The Medicines Company. More recently, he was Chief Business Officer of Histogenics and Sherlock Biosciences. Major Estimate Revision • Dec 10
Analysts update estimates The company's losses in 2021 are expected to improve with analysts raising their consensus EPS forecasts from -CA$0.75 to -CA$0.46. Revenue estimate was approximately flat at CA$9.33m. The Pharmaceuticals industry in Canada is expected to see a 23% decline in net income next year. The consensus price target was lowered from CA$18.62 to CA$17.02. Share price stayed mostly flat at CA$3.92 over the past week. Major Estimate Revision • Dec 03
Analysts update estimates The company's losses in 2021 are expected to improve with analysts raising their consensus EPS forecasts from -CA$0.75 to -CA$0.44. Revenue estimate was approximately flat at CA$9.33m. The Pharmaceuticals industry in Canada is expected to see a 23% decline in net income next year. The consensus price target of CA$18.62 was unchanged from the last update. Share price stayed mostly flat at CA$3.95 over the past week. Duyuru • Nov 25
Antibe Therapeutics Inc. Announces Board Appointments Antibe Therapeutics Inc. announced the appointment of Robert E. Hoffman and Jennifer McNealey to its Board of Directors. Until his retirement last month, Mr. Hoffman was Chief Financial Officer of Heron Pharmaceuticals. His career in the sector began in 1997 at Arena Pharmaceuticals, where he rose to become CFO, holding that position for ten years. Ms. McNealey is a senior financial and strategy executive with a considerable breadth of experience in the biotechnology sector, as an analyst, portfolio manager, information provider and expert in corporate communications and investor relations. She is currently Vice President, Investor Relations and Strategy for Calithera Biosciences. Since 2013, Ms. McNealey has served on the board of Enzon Pharmaceuticals. Major Estimate Revision • Nov 19
Analysts update estimates The 2021 consensus revenue estimate increased from CA$7.57m to CA$9.36m. Earning per share (EPS) estimate was further reduced from -CA$0.052 to -CA$0.075 for the same period. The Pharmaceuticals industry in Canada is expected to see an average net income growth of 68% next year. The consensus price target of CA$1.86 was unchanged from the last update. Share price is down by 1.2% to CA$0.40 over the past week. Reported Earnings • Nov 15
Second quarter 2021 earnings released: CA$0.021 loss per share The company reported a soft second quarter result with increased losses and weaker control over expenses, although revenues were improved. Second quarter 2021 results: Revenue: CA$2.87m (up 26% from 2Q 2020). Net loss: CA$7.95m (loss widened 61% from 2Q 2020). Over the last 3 years on average, earnings per share has fallen by 15% per year but the company’s share price has increased by 61% per year, which means it is well ahead of earnings. Analyst Estimate Surprise Post Earnings • Nov 15
Revenue and earnings beat expectations Revenue exceeded analyst estimates by 42%. Earnings per share (EPS) also surpassed analyst estimates by 100%. Over the next year, revenue is forecast to grow 24%, compared to a 147% growth forecast for the Pharmaceuticals industry in Canada. Duyuru • Nov 12
Antibe Therapeutics Inc.(TSXV:ATE) dropped from S&P/TSX Venture Composite Index Antibe Therapeutics Inc.(TSXV:ATE) dropped from S&P/TSX Venture Composite Index Is New 90 Day High Low • Oct 29
New 90-day low: CA$0.32 The company is down 16% from its price of CA$0.38 on 30 July 2020. The Canadian market is down 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 1.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CA$4.96 per share. Price Target Changed • Sep 26
Price target lowered to CA$1.86 Down from CA$2.12, the current price target is an average from 5 analysts. The new target price is 417% above the current share price of CA$0.36. As of last close, the stock is down 5.3% over the past year. Is New 90 Day High Low • Sep 18
New 90-day low: CA$0.36 The company is down 20% from its price of CA$0.46 on 19 June 2020. The Canadian market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 3.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share. Duyuru • Aug 25
Antibe Therapeutics Inc. to Report Q1, 2021 Results on Aug 24, 2020 Antibe Therapeutics Inc. announced that they will report Q1, 2021 results on Aug 24, 2020 Duyuru • Jul 31
Antibe Therapeutics Inc. Auditor Raises 'Going Concern' Doubt Antibe Therapeutics Inc. filed its Annual on Jul 24, 2020 for the period ending Mar 31, 2020. In this report its auditor, Ernst & Young LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern. 
